Dosing & Uses
Dosage Forms & Strengths
Elevated Intraocular Pressure
Lumigan (0.01% or 0.03%): 1 gtt in affected eye qDay in evening
Hypotrichosis of the Eyelashes
Latisse (0.03%): 1 gtt on disposable sterile applicator & apply evenly along skin of upper eyelid margin at base of eyelashes
Safety & efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Conjunctival hyperemia (25-45%)
Growth of eyelashes (15-45%)
Ocular pruritus (15-45%)
Ocular dryness (3-10%)
Visual disturbance (3-10%)
Ocular burning (3-10%)
Foreign body sensation (3-10%)
Ocular pain (3-10%)
Pigmentation of the periocular skin (3-10%)
Superficial punctate keratitis (3-10%)
Eyelid erythema (3-10%)
Ocular irritation (3-10%)
Eyelash darkening (3-10%)
Ocular discharge (1-3%)
Allergic conjunctivitis (1-3%)
Increases in iris pigmentation (1-3%)
Conjunctival edema (1-3%)
Frequency Not Defined
Eyelids: burning sensation, edema, irritation, pruritus
Madarosis and trichorrhexis
Periorbital and lid changes associated with a deepening of the eyelid sulcus
Rash (including macular, erythematous, and pruritic limited to the eyelids and periorbital region)
Skin discoloration (periorbital)
Caution with aphakic and pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
Contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses
Caution in active intraocular inflammation (e.g., uveitis)
Take soft contact lenses out when applying, reinsert at least 15 min later
Bacterial keratitis may result from inadvertent contamination of multi-dose ophthalmic solutions
May permanently change brown pigmentation of the iris, eyelid skin, and eyelashes
Not recommended for patients <16 years
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Prostaglandin analog; increases outflow of aqueous humor
Absorption: No significant systemic accumulation
Half Life: 45 min
Peak plasma time: ≤10 min
Onset of action: 4hr (IOP reduction)
Peak effect: 8-12hr
Protein binding: 88%
Vd: 0.67 L/kg
Metabolism: Oxydation; N-deethylation and glucoronidation
Excretion: Urine (67%); feces (25%)
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.